Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, dapoxetine (Priligy®) cannot be endorsed for use within NHS Wales for the treatment of premature ejaculation in men aged 18 to 64 years old. |
||
|
||
Medicine details |
||
| Medicine name | dapoxetine (Priligy®) | |
| Formulation | Film-coated tablet | |
| Reference number | 1671 | |
| Indication | Treatment of premature ejaculation in men aged 18 to 64 years old |
|
| Company | A. Menarini Farmaceutica Internazionale SRL | |
| BNF chapter | Obstetrics, gynaecology & urinary tract disorders | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 07/08/2012 | |